DekaBank Deutsche Girozentrale Sells 9,191 Shares of Zymeworks Inc. (NYSE:ZYME)

DekaBank Deutsche Girozentrale decreased its position in Zymeworks Inc. (NYSE:ZYME) by 70.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,843 shares of the company’s stock after selling 9,191 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zymeworks were worth $40,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Morgan Stanley lifted its stake in Zymeworks by 6.0% in the 4th quarter. Morgan Stanley now owns 5,573,380 shares of the company’s stock valued at $43,807,000 after acquiring an additional 314,405 shares in the last quarter. BlackRock Inc. lifted its stake in Zymeworks by 371.4% in the 2nd quarter. BlackRock Inc. now owns 3,542,678 shares of the company’s stock valued at $30,609,000 after acquiring an additional 2,791,105 shares in the last quarter. Rubric Capital Management LP lifted its stake in Zymeworks by 12.5% in the 3rd quarter. Rubric Capital Management LP now owns 2,651,394 shares of the company’s stock valued at $16,810,000 after acquiring an additional 293,817 shares in the last quarter. Vanguard Group Inc. lifted its stake in Zymeworks by 5.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,383,986 shares of the company’s stock valued at $15,114,000 after acquiring an additional 131,604 shares in the last quarter. Finally, Samsara BioCapital LLC lifted its stake in Zymeworks by 66.9% in the 4th quarter. Samsara BioCapital LLC now owns 1,620,687 shares of the company’s stock valued at $12,739,000 after acquiring an additional 649,700 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Stock Performance

NYSE ZYME opened at $8.85 on Thursday. Zymeworks Inc. has a 52 week low of $6.01 and a 52 week high of $13.14. The stock has a market capitalization of $624.54 million, a price-to-earnings ratio of -5.09 and a beta of 1.14. The stock’s 50 day moving average price is $10.86 and its two-hundred day moving average price is $9.53.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.19. Zymeworks had a negative return on equity of 26.20% and a negative net margin of 156.12%. The company had revenue of $16.93 million for the quarter, compared to analysts’ expectations of $18.32 million. On average, equities research analysts forecast that Zymeworks Inc. will post -1.04 EPS for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.